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Introduction
Any review of modern transfusion therapy would be incom-
plete without considerable discussion of hemoglobin-based
oxygen carriers (HBOCs). This abbreviation is the preferred
term for the class of transfusable fluids also known as ‘oxygen
therapeutics’. The biologic goal of transfusion therapy is to
preserve tissue perfusion in order to minimize the damage –
both physiologic and structural – that results from prolonged
or repeated episodes of ischemia [1,2]. Oxygen-carrying
solutions with crystalloid and colloid elements may be effec-
tive in many clinical situations. For example, in a simple analyt-
ical model designed to illustrate how HBOCs might be used
in surgery, a red blood cell (RBC) substitute of the first gener-
ation, currently in clinical testing, is projected to replace up to
60% of the current use of allogeneic RBCs [2].
A brief note on development of hemoglobin-
based oxygen carriers
Efforts to find a replacement for blood reported in the medical
literature can be traced back further than a century [3].
Although earlier proposals for oxygen therapeutics were
imaginative and interesting, few came to fruition. Failure to
achieve success rested with the lack of scientific knowledge
about blood; furthermore, the technology needed to create a
useful blood substitute solution was lacking. The crisis of
infectious disease transmission in the 1980s [4] generated
renewed interest, and engendered within the development
process a sense of urgency, because use of blood replace-
ment fluids allows the adverse consequences of transfusions
to be avoided. The potential for transmission of HIV and a
more scientific approach to transfusion medicine stimulated
development of a new generation of potentially useful solu-
tions that could substitute for blood. However, although many
of the blood substitutes showed promise in the initial preclini-
cal testing phase, few survived the rigors of regulatory over-
sight and safety considerations. In the mid- to late 1980s as
many as 12 solutions were proposed for use as HBOCs in
the clinical setting.
Once the challenges of molecular stability and ensuring
appropriate oxygen affinity were addressed, some com-
pounds entered the complex world of clinical testing [5].
Through a variety of molecular modifications, more stable
hemoglobin tetramers or polymers were created that effec-
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Abstract
Transfusable fluids that may be used as alternatives to red blood cell transfusion offer the promise of
preserving tissue perfusion and minimizing hypoxic cellular damage, and this promise may soon be
fulfilled. Clinical testing of hemoglobin-based oxygen carriers has faced and met challenges involving
molecular design, safety, efficacy, and regulatory requirements. Three leading candidates have
emerged: two human (PolyHeme® and HemoLink™) and one bovine-based hemoglobin solution
(Hemopure®). Because a survival benefit has been difficult to demonstrate, avoidance of allogeneic
transfusion has been adopted as the standard efficacy end-point for these agents. An update on
clinical trial status is provided, and the potential utility of hemoglobin-based oxygen carriers in surgery
combined with intraoperative autologous donation is discussed.
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tively minimized renal clearance of the protein [6]. By the early
to mid-1990s it became clear that pure solutions of hemoglo-
bin were needed as starting materials, and technologies were
being developed to synthesize such compounds [7,8]. Chem-
ical modifications were applied to achieve the most desirable
molecular effects (i.e. improved persistence and lowered
oxygen affinity), and it became possible to manufacture rea-
sonably large quantities of pharmaceutical grade HBOC solu-
tions [7]. Efforts to create modified hemoglobin through
recombinant technology were undertaken, with varying
degrees of success [6]. Unfortunately, these latter efforts
proved to be prohibitively expensive. Scaling the process up
to produce the quantities required to meet anticipated
demands were feared to exceed the costs that could be sus-
tained in the eventual marketplace. Nevertheless, this recom-
binant technology remains an excellent approach for future
research endeavors, and efforts at genetically determined
site-specific modification and cross-linking are ongoing,
although they are confined to laboratory exercises [6]. Given
the prolonged period of time required to take a laboratory
concept through the regulatory process, another decade may
pass before any agents arising from recombinant technology
are proven effective and safe to market for general use.
Leading candidate hemoglobin-based oxygen
carriers for regulatory approval
Three forms of HBOCs are in advanced testing stages in the
regulatory approval process [9]. One bovine hemoglobin-
based solution under development relies on the naturally low
affinity of bovine hemoglobin for oxygen as a major rationale
for its use. In addition, there are two human hemoglobin-
based solutions – one a polymer and the other an oligomeric
solution containing a polymeric compound and some cross-
linked hemoglobin tetramer. Beyond their ability to carry and
deliver oxygen to tissues, these solutions have different
physicochemical and physiological properties as well as dif-
ferent biologic activities. Characteristics of these three candi-
date HBOCs are summarized in Table 1.
Through complex regulatory processes, these products have
been negotiating toward licensure for clinical use, including
phase III testing, whereas other solutions have not pro-
gressed this far [10]. Lessons from unsuccessful efforts are
difficult to glean because data from an unsuccessful experi-
ment are rarely published. Thus, the field as a whole is often
deprived of the opportunity to benefit from experience and is
prone to repeat the mistake, if indeed it is a preventable error.
Some of this information may be revealed when investigators
gather to compare notes or present research findings, but it
is not generally formalized or broadly disseminated.
One topic of active debate over the past decade was the def-
inition of ‘efficacy’ as it relates to HBOCs. Demonstrating sur-
vival benefit in most clinical models is very difficult, and
correlating oxygen delivery and use parameters with survival
outcome is equally difficult. Borrowing from other areas of
transfusion medicine, avoidance of allogeneic transfusion has
almost become a universal marker of efficacy for those solu-
tions currently undergoing clinical trials [6].
Recent clinical trials and current status of
hemoglobin-based oxygen carriers
Both bovine and human HBOCs have recently been tested in
phase II/III clinical studies (Table 2). PolyHeme® (Northfield
Table 1
Characteristics of three hemoglobin-based oxygen carriers being tested in advanced clinical trials
Product name
Details PolyHeme® Hemopure® (HBOC-201) HemoLink™ (Hb-raffimer)
Company Northfield Laboratories  Biopure Corporation  Hemosol Inc. 
(Evanston, IL, USA) (Cambridge, MA, USA) (Toronto, Canada)
Modification method Pyridoxylation and  Glutaraldehyde polymerization  Crosslinking with o-raffinose 
glutaraldehyde polymerization  (polymer) (oligomer)
(polymer)
Hemoglobin source Human hemoglobin Bovine hemoglobin Human hemoglobin
Hemoglobin concentration (g/dl) 10 13 10
Molecular weight Not reported  Average molecular weight:  <64 kDa: <5%
(< 64 kDa; 1.0%) 250 kDa 64–500 kDa: >90%
>500 kDa: <3%
pH Not reported 7.6–7.9 7.5
P50 (torr) 26–32 38 52
Viscosity (cP) Not reported 1.3 1.14
Shelf life  >1 year >1 year >1 year 
HBOC, hemoglobin-based oxygen carrier; P50, partial pressure of oxygen at which hemoglobin is 50% saturated.S63
Laboratories, Evanston, IL, USA), a human hemoglobin-based
polymeric HBOC, has been shown to be effective in reducing
mortality of patients with severe acute anemia [11]. When
compared with severely anemic historical control individuals
who refused allogeneic RBC transfusion on religious
grounds, the PolyHeme group had a lower mortality at com-
parable erythrocytic hemoglobin concentration. Hemopure®
(Biopure Corporation, Cambridge, MA, USA), a bovine polymeric
hemoglobin, and HemoLink™ (Hemosol, Inc., Mississauga,
Ontario, Canada), an oligomeric human hemoglobin-based
HBOC, have been shown to reduce allogeneic RBC transfu-
sion in patients undergoing cardiac surgery [12].
Currently, PolyHeme is being tested in a pivotal phase III pre-
hospital trauma study [13]. The study proposes to demon-
strate the safety and efficacy of PolyHeme in improving
survival when it is used to treat severely injured bleeding
trauma patients at the scene of injury and during transit to the
hospital. Of note, this study will be conducted under the
informed consent waiver provision. Because of the nature
and extent of injuries, patients eligible for the study will be
unable to provide informed consent. Federal regulations allow
clinical research without informed consent under certain
emergency settings. It is anticipated that over 700 patients
will be enrolled in the study from approximately 20 level I
trauma centers across the country.
In 2001, Hemopure (hemoglobin glutamer-250 or HBOC-
201) was approved in South Africa for treatment of adult sur-
gical patients who are acutely anemic and for the purpose of
eliminating, reducing, or delaying the need for allogeneic
RBC transfusion in these patients [14]. In October 2002,
Biopure filed a biologic license application to the US Food
and Drug Administration to market Hemopure in the USA for
a similar indication in orthopedic surgical patients. In August
2003, the Food and Drug Administration requested additional
information [15], including clarification of certain clinical and
preclinical data, before ruling on whether to allow marketing
of the product.
Some of the trials were discontinued early, such as the
diaspirin cross-linked hemoglobin study, which demonstrated
higher mortality in treated patients than in nontreated ones
[10].
In early 2003, Hemosol voluntarily suspended a phase IIb
cardiac surgery study when it discovered an imbalance in the
incidence of certain adverse cardiac events, with higher
numbers occurring in the HemoLink-treated group. Hemosol
elected to terminate the study and is currently investigating the
cause of the imbalance [16], which is thought to be related to
the higher rate of diabetes in the HemoLink-treated group.
In addition, Sangart Corporation (San Diego, CA, USA) has
reported positive results from a phase Ib/II clinical trial in
Sweden of Hemospan™ (MP4), a HBOC based on human
hemoglobin conjugated to maleimide polyethylene glycol. The
trial enrolled patients undergoing orthopedic surgical proce-
dures [17].
Perioperative use of hemoglobin-based
oxygen carriers
Given the sensitivity to transfusion-related illness and the
general fear by the public and physicians of blood transfu-
sions, it is common for patients to ask for alternatives to
banked blood. Almost all of the paradigms and algorithms for
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Table 2
Recently published clinical studies of three leading hemoglobin-based oxygen carriers
Product name
Details PolyHeme® Hemopure® (HBOC-201) HemoLink™ (Hb-raffimer)
Company Northfield Laboratories  Biopure Corporation  Hemosol Inc. 
(Evanston, IL, USA) (Cambridge, MA, USA) (Ontario, Canada)
Indicated use Trauma/urgent surgery Cardiac surgery Coronary artery bypass graft
Clinical trial status Phase III Phase III Phase II/III
Study design Multicenter, randomized,  Multicenter, randomized,  Multicenter, randomized, 
double blind double blind single blind
End-point Mortality  Transfusion avoidance Transfusion avoidance
Major findings PolyHeme increased survival Hemopure reduced allogeneic  HemoLink reduced allogeneic 
red cell transfusion  red cell transfusion
Current status Phase III mortality study Filed BLA Clinical study suspended pending 
further analysis
Reference Gould and coworkers [11] Levy and coworkers [12] Hill and coworkers [19]
BLA, Biologic License Application.S64
avoiding transfusion tend to be resource intensive and expen-
sive, and still do not eliminate all risk. Alternatives can be
sought, and use of HBOCs as part of intraoperative autolo-
gous donation (IAD) makes a great deal of sense.
In the IAD model of autologous transfusion, blood lost during
surgery is recovered and reinfused into the patient. Using
hemodilution and an oxygen therapeutic to replace some of
the oxygen-carrying capacity of the RBCs removed minimizes
blood lost during procedures. In addition, the potential for
impaired tissue perfusion is lessened. In a phase II clinical
trial using the IAD concept in cardiac surgery, decreased
exposure to allogeneic RBCs was noted in the population
randomly assigned to the HBOC arm. Moreover, the effect
appeared to be sustained over time, beyond the immediate
operative period, with a real proportion of the population
never having exposure to allogeneic blood or blood products
[18]. In light of these findings, there is promise for even the
first generation of HBOCs to have an impact on patient care
and outcome.
Conclusion
While trials continue with the three major solutions, research
efforts continue to search for alternatives and for newer for-
mulations and concepts to apply. As our understanding of the
physiology of oxygen delivery and use improves, so will the
concepts that underlie the design of HBOCs. As our appreci-
ation of the physiology of shock and resuscitation at many
levels grows, it is to be expected that the desire to create
specific HBOCs to meet the needs of specific situations will
grow. Furthermore, as clinical experience and the knowledge
base grows, it will become increasingly possible to develop
more effective therapies. The field remains exciting and rele-
vant. Even with a better appreciation of when to transfuse a
patient, the options of what to use remain few. The addition of
HBOCs to the armamentarium is welcome and will be
embraced because they have allowed us to focus on the
underlying issues of when to transfuse and what to use to
accomplish our goal.
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